Vivos Acquires Equity and Patents from SOD Sciences for $12 Million
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Vivos closed a strategic partnership with SOD Sciences on October 26, 2026. Vivos acquired an 11% equity interest in SOD Sciences, along with 50% ownership of SOD's pseudohypoxia patent and 50% ownership of the ReBalU Primed Cell Test. The acquisition was made in exchange for $12 million of Vivos Series D Convertible Preferred Stock.
Why it matters
The acquisition expands Vivos' intellectual property portfolio. SOD Sciences' ReBalU Protocol is built on the principle that chronic diseases stem from antioxidant system imbalances, a condition that accounts for 90% of the nation's $5.3 trillion in annual health care spending.
Vivos is advancing its product line by securing patents through USPTO filings and gaining 510K clearances for an alternative to CPAP technology.
Who's involved
- VivosAcquired equity and key patents from SOD Sciences for strategic assets.
- United States Patent and Trademark OfficeAdministers patent filings for Vivos.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- VivosSpeculative
Vivos could increase its revenue potential by integrating strategic assets and patents from SOD Sciences.
Keep exploring
The entities involved
-
Vivos
California-based company, that provdes hardened underground shelters designed to withstand future disasters and life-extinction catastrophes
Nothing else this week.